Treatments

MS therapies: what is in the Pipeline

This webinar was presented at the first International Neuroimmunology Conference INIC 2024 1-2 March 2024 in Riyadh, Saudi Arabia. Professor Nicolas Grigoriadis talked about advancements in treating multiple sclerosis (MS) – from general treatments like Copaxone and interferons to more targeted therapies, such as monoclonal antibodies, which focus on controlling T and B cell activity. The current research indicates that microglial cells play a crucial role in ongoing neurodegeneration and disability progression, suggesting the need for treatments targeting these cells. New therapies in the pipeline, such as anti-CD20 monoclonal antibodies and BTK inhibitors, show promise in addressing both B cells in the brain and microglial activity to better manage MS progression.

BIOGRAPHY

Nikolaos Grigoriadis

Professor of Neurology at the Aristotle University of Thessaloniki

Dr Nikolaos Grigoriadis graduated from the Faculty of Medicine of the Aristotle University of Thessaloniki. He did his PhD thesis and residency in Neurology in the same institution. He has been specialized in clinical and experimental Neuroimmunology and CNS immunopathology in a number of research centers and institutions abroad.

He is now Professor of Neurology at the Aristotle University of Thessaloniki and Head of the of the B’ Dept of Neurology, AHEPA University Hospital, the MS Centre and the Laboratory of Experimental Neurology and Neuroimmunology (www.neuroimmunology.gr).

Professor Grigoriadis is member of various international scientific committees such as the European School of Neuroimmunology, ParadigMS, the subcommittee of ENS for Multiple Sclerosis, the ECTRIMS committee (until 2010), Co-founder and Secretary of the Hellenic Academy of Neuroimmunology (www.helani.gr). He is President of the Hellenic Neurological Society. He is Ad Hoc reviewer in more than 40 international scientific journals, co-ordinator in more than 40 multicenter clinical trials for MS and principal investigator in collaborative research projects for experimental cell therapies in CNS autoimmune demyelination.
His field of interests are: Neuroimmunology; Multiple sclerosis; experimental models of autoimmune diseases (EAE etc); neurodegeneration; immunomodulation; cell therapies. He has published more than 180 papers in peer reviewed journals. He has been awarded several times for his scientific work.